Ad Com votes in favor of BioMarin's Vimizim

BioMarin Pharmaceutical (BMRN) secures an Ad Com vote in favor of approval of Vimizim for the treatment of Morquio A syndrome. 19 panel members voted in favor of the drug's use in all MPS IVA patients, 1 for approval in a subgroup, and 1 for not recommending approval.

A PDUFA action date of Feb. 28 has been assigned.

Shares are up 3.1% AH after trading resumed from the earlier halt.

Previous: FDA says BioMarin drug results in "modest" improvements

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs